There were 584 press releases posted in the last 24 hours and 171,218 in the last 365 days.

Graves Ophthalmopathy Pharmaceutical and Healthcare Pipeline Review H2

Wise.Guy12

Wise.Guy.

Graves Ophthalmopathy Treatment Pipeline Review H2 2017

PUNE, INDIA, January 6, 2017 /EINPresswire.com/ -- GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/535865-graves-ophthalmopathy-pipeline-review-h1-2016

Graves' Ophthalmopathy - Pipeline Review, H1 2016
Summary
The report provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects.
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy
- The report reviews pipeline therapeutics for Graves' Ophthalmopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Graves' Ophthalmopathy therapeutics and enlists all their major and minor projects
- The report assesses Graves' Ophthalmopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Graves' Ophthalmopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Graves' Ophthalmopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=535865

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Graves' Ophthalmopathy Overview 6
Therapeutics Development 7
Pipeline Products for Graves' Ophthalmopathy - Overview 7
Graves' Ophthalmopathy - Therapeutics under Development by Companies 8
Graves' Ophthalmopathy - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Graves' Ophthalmopathy - Products under Development by Companies 11
Graves' Ophthalmopathy - Companies Involved in Therapeutics Development 12
Genmab A/S 12
Neothetics, Inc. 13
Novartis AG 14
Yuhan Corporation 15
Graves' Ophthalmopathy - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
(fluticasone propionate + salmeterol xinafoate) - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/535865-graves-ophthalmopathy-pipeline-review-h1-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here